Boothbay Fund Management’s Terns Pharmaceuticals TERN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-486,170
| Closed | -$25.6M | – | 2627 |
|
|
2026
Q1 | $25.6M | Buy |
486,170
+39,162
| +9% | +$1.61M | 0.33% | 25 |
|
|
2025
Q4 | $18.1M | Buy |
447,008
+268,133
| +150% | +$6.2M | 0.27% | 54 |
|
|
2025
Q3 | $1.34M | Buy |
178,875
+122,411
| +217% | +$782K | 0.02% | 718 |
|
|
2025
Q2 | $211K | Sell |
56,464
-70,366
| -55% | -$220K | ﹤0.01% | 1230 |
|
|
2025
Q1 | $350K | Hold |
126,830
| – | – | 0.01% | 997 |
|
|
2024
Q4 | $703K | Sell |
126,830
-6
| -0% | -$41 | 0.02% | 753 |
|
|
2024
Q3 | $1.06M | Sell |
126,836
-39,804
| -24% | -$327K | 0.02% | 733 |
|
|
2024
Q2 | $1.13M | Buy |
166,640
+151,208
| +980% | +$916K | 0.03% | 674 |
|
|
2024
Q1 | $101K | Sell |
15,432
-10,934
| -41% | -$71.4K | ﹤0.01% | 1417 |
|
|
2023
Q4 | $171K | Hold |
26,366
| – | – | ﹤0.01% | 1358 |
|
|
2023
Q3 | $133K | Sell |
26,366
-24,374
| -48% | -$155K | ﹤0.01% | 1509 |
|
|
2023
Q2 | $444K | Sell |
50,740
-76,812
| -60% | -$895K | 0.01% | 1160 |
|
|
2023
Q1 | $1.51M | Buy |
127,552
+1,670
| +1% | +$16K | 0.03% | 808 |
|
|
2022
Q4 | $1.28M | Sell |
125,882
-9,837
| -7% | -$65.5K | 0.03% | 793 |
|
|
2022
Q3 | $799K | Buy |
135,719
+29,007
| +27% | +$108K | 0.02% | 989 |
|
|
2022
Q2 | $265K | Buy |
+106,712
| New | +$213K | 0.01% | 1550 |
|
Other funds holding TERN
Boothbay Fund Management's TERN Position: Q2 2026 in Review
Boothbay Fund Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 486,170 shares — an estimated $25.6M sold.
Boothbay Fund Management first reported a position in TERN in Q2 2022 and held it in 16 quarters. The position peaked at $25.6M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.
- Boothbay Fund Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 486,170 Terns Pharmaceuticals shares in Q2 2026, an estimated $25.6M.
- Boothbay Fund Management first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 16 quarters.
- Boothbay Fund Management's Terns Pharmaceuticals position peaked at $25.6M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.